公开(公告)号：US20030119058A1

公开(公告)日：2003-06-26

申请号：US10058124

申请日：2002-01-29

Applicant: Osteometer A/S

Inventor： Per Qvist ,  Martin Bonde

IPC: G01N033/53 ,  C07K014/78 ,  G01N033/537 ,  G01N033/543 ,  C07K002/00 ,  C07K004/00 ,  C07K005/00 ,  C07K007/00 ,  C07K014/00 ,  C07K016/00 ,  C07K017/00 ,  A61K038/00 ,  A61K038/04 ,  C07K001/00 ,  C09H001/00 ,  A61K038/17 ,  G01N033/545

CPC classification number: G01N33/6887 ,  C07K16/18 ,  G01N2800/108 ,  Y10S435/975 ,  Y10S436/815

Abstract: A method of assaying collagen fragments in body fluids, including bringing a sample of body fluid in contact with at least one immunological binding partner for the collagen fragments, said binding partner being immunoreactive with synthetic peptides, the sequences of which are essentially derived from collagen and containing potential sites for cross-linking. The immunological binding partners are incorporated, either as whole antibodies or as immunologically active fragments thereof, in an assay for quantitative determination of collagen fragments in the sample. In addition to being contacted with the immunological binding partner(s), the sample may be brought into direct contact with the corresponding synthetic peptide. The invention further comprises a test kit and specific means for carrying out the method. The structure of specific peptides is also described.

Abstract translation: 一种测定体液中的胶原片段的方法，包括使体液样品与至少一种用于胶原片段的免疫结合配偶体接触，所述结合配偶体与合成肽免疫反应，其序列基本上衍生自胶原和 含有潜在的交联网站。 将免疫学结合配偶体作为完整抗体或其免疫活性片段掺入用于定量测定样品中胶原片段的测定中。 除了与免疫结合配偶体接触外，样品可以与相应的合成肽直接接触。 本发明还包括测试套件和用于执行该方法的特定装置。 还描述了特定肽的结构。

公开(公告)号：US20030109670A1

公开(公告)日：2003-06-12

申请号：US10072602

申请日：2002-02-11

Applicant: University of Utah Research Foundation

Inventor： Baldomero M. Olivera ,  J. Michael McIntosh ,  Maren Watkins ,  James E. Garrett ,  Lourdes J. Cruz ,  Michelle Grilley ,  Robert A. Schoenfeld ,  Craig S. Walker ,  Reshma P. Shetty ,  Robert M. Jones

IPC: A61K038/00 ,  C07K005/00 ,  C07K016/00 ,  C07K007/00 ,  C07K017/00 ,  C07H021/04 ,  C12N001/20 ,  C12N015/00 ,  C12N015/09 ,  C12N015/63 ,  C12N015/70 ,  C12N015/74 ,  C12N005/00 ,  C12N005/02

CPC classification number: C07K14/43504 ,  A61K38/00

Abstract: The present invention is directed to conotoxin peptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated ion channels, voltage-gated ligand channels and/or receptors. The invention is further directed to nucleic acid sequences encoding the conotoxin peptides and encoding propeptides, as well as the propeptides.

Abstract translation: 本发明涉及芋螺毒素肽，其衍生物或药学上可接受的盐。 本发明进一步涉及该肽，其衍生物和其药学上可接受的盐在治疗与电压门控离子通道，电压门控配体通道和/或受体相关的病症中的用途。 本发明还涉及编码芋螺毒素肽和编码前肽以及前肽的核酸序列。

公开(公告)号：US20030108567A1

公开(公告)日：2003-06-12

申请号：US10287892

申请日：2002-11-04

Inventor： Dominique P. Bridon ,  Benoit L'Archeveque ,  Alan M. Ezrin ,  Darren L. Holmes ,  Anouk Leblanc ,  Serge St. Pierre

IPC: A61K039/385 ,  C07K014/575 ,  A61K038/24 ,  C07K005/00 ,  C07K007/00 ,  C07K016/00 ,  C07K017/00 ,  A61K038/00 ,  C07K001/00 ,  C07K014/00 ,  A61K038/27

CPC classification number: C07K14/005 ,  A61K38/00 ,  A61K47/643 ,  C07K14/57563 ,  C07K14/605 ,  C12N2740/16122

Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.

Abstract translation: 公开了改进的促胰岛素肽。 修饰的促胰岛素肽能够形成肽酶稳定的促胰岛素肽。 修饰的促胰岛素肽能够与一种或多种血液成分形成共价键以形成缀合物。 缀合物可以在体内或离体形成。 施用修饰的肽以治疗患有糖尿病和其他相关疾病的人。

公开(公告)号：US20030104010A1

公开(公告)日：2003-06-05

申请号：US10203280

申请日：2002-10-07

Inventor： Jan Raa ,  Aud Katherine Herland Berstad ,  Hilde Sunove Waleur Bakke ,  Bjorn Haneberg ,  Inger Lise Haugen ,  Johan Holst ,  Liba Janakova ,  Gro Ellen Korsvold ,  Fredrik Oftung

IPC: C12Q001/68 ,  A61K039/12 ,  A61K039/145 ,  A61K045/00 ,  A61K047/00 ,  C07K002/00 ,  C07K004/00 ,  C07K005/00 ,  C07K007/00 ,  C07K014/00 ,  C07K016/00 ,  C07K017/00 ,  A61K038/00

CPC classification number: A61K39/145 ,  A61K39/12 ,  A61K39/39 ,  A61K2039/541 ,  A61K2039/543 ,  A61K2039/55583 ,  C12N2760/16134

Abstract: Adjuvant for mucosal vaccines which modulates the effects of substances, including vaccine antigens in contact with mucosal body surfaces.

Abstract translation: 用于调节物质影响的粘膜疫苗的辅助剂，包括疫苗抗原与粘膜体表面接触。

公开(公告)号：US20030088080A1

公开(公告)日：2003-05-08

申请号：US09885453

申请日：2001-06-21

Inventor： Didier Communi ,  Vincent Lannoy ,  Cedric Govaerts ,  Marc Parmentier ,  Michel Detheux

IPC: C07H021/02 ,  C07H021/04 ,  C07K005/00 ,  C07K007/00 ,  C07K016/00 ,  C07K017/00 ,  A61K038/00

CPC classification number: C07K14/705 ,  A01K2217/05

Abstract: The present invention is related to a novel G-protein coupled receptor having an amino acid sequence which presents more than 75% sequence identity with the sequence SEQ ID NO. 1. The present invention further comprises a method for screening a substance as a potential agonist, reverse agonist, or antagonist to the receptor of the invention. The present invention further comprises a diagnostic method to identify expression of the receptor in target tissues or cells.

Abstract translation: 本发明涉及具有氨基酸序列的新型G蛋白偶联受体，所述氨基酸序列与序列SEQ ID NO： 本发明还包括用于筛选作为本发明的受体的潜在激动剂，反向激动剂或拮抗剂的物质的方法。 本发明还包括鉴定受体在靶组织或细胞中的表达的诊断方法。

公开(公告)号：US20030064916A1

公开(公告)日：2003-04-03

申请号：US09277064

申请日：1999-03-26

Inventor： LINDA A. SHERMAN

IPC: A61K038/28 ,  G01N033/53 ,  A61K038/16 ,  C07K002/00 ,  C07K004/00 ,  C07K005/00 ,  C07K007/00 ,  C07K014/00 ,  C07K016/00 ,  C07K017/00 ,  A61K038/00

CPC classification number: C07K14/4746 ,  A61K38/00 ,  A61K39/00 ,  A61K2039/5158 ,  C07K14/71 ,  C07K14/82 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/732 ,  G01N33/505 ,  G01N33/56972 ,  G01N33/6854

Abstract: The present invention relates to methods, compositions, and peptides useful in activating CTLs in vivo with specificity for particular antigenic peptides. The invention also discloses the use of activated CTLs in vivo for the diagnosis and treatment of a variety of disease conditions, and compositions appropriate for these uses. Diagnostic systems, components, and methods are also described herein.

公开(公告)号：US20030064075A1

公开(公告)日：2003-04-03

申请号：US09900963

申请日：2001-07-10

Inventor： Claudine Guerin-Marchand ,  Pierre Druilhe

IPC: A61K039/015 ,  C12N009/02 ,  A61K039/395 ,  A61K039/00 ,  A61K039/002 ,  A61K039/12 ,  C07K002/00 ,  C07K004/00 ,  C07K005/00 ,  C07K007/00 ,  C07K014/00 ,  C07K016/00 ,  C07K017/00 ,  A61K038/00 ,  C07H021/04

CPC classification number: A61K39/015 ,  A61K39/00 ,  C07K14/445 ,  C07K16/205 ,  G01N33/56905 ,  Y02A50/412 ,  Y10S530/82 ,  Y10S530/822

Abstract: The invention discloses a molecule or polypeptide composition characterized by the presence in its structure of one or more peptide sequences bearing all or part of one or more T epitopes, and possibly other epitopes, particularly B epitopes, charactistic of proteins resulting from the infectious activity of P. falciparum in hepatic cells. Also disclosed is the use of these molecules in tests, and a set or kits for in vitro diagnosis of paludism from a biological sample from the individual in whom the disease is to be detected. The use of these molecules in compositions for paludism vaccines is also covered.

Abstract translation: 本发明公开了一种分子或多肽组合物，其特征在于在其结构中存在一个或多个携带一个或多个T表位的全部或部分的肽序列，以及可能的其他表位，特别是B表位，由感染活性产生的蛋白质的特征 恶性疟原虫在肝细胞中。 还公开了这些分子在测试中的用途，以及用于体外诊断来自要检测疾病的个体的生物样品的一套或多种试剂盒。 这些分子在组合物中的应用也被覆盖。

公开(公告)号：US20030060408A1

公开(公告)日：2003-03-27

申请号：US10076071

申请日：2002-02-13

Inventor： David Bar-Or ,  C. Gerald Curtis ,  Edward Lau ,  Nagaraja K.R. Rao ,  James V. Winkler ,  Wannell M. Crook

IPC: A61K038/00 ,  C07K005/00 ,  C07K007/00 ,  C07K016/00 ,  C07K017/00

CPC classification number: C07K5/0827 ,  A61K38/00 ,  C07K5/1027 ,  C07K14/47 ,  C07K14/4715

Abstract: The invention provides a method of reducing the damage done by reactive oxygen species (ROS) in an animal. The invention also provides a method of reducing the concentration of a metal in an animal. These methods comprise administering to the animal an effective amount of a metal-binding compound as further described in the application. The invention further provides a method of reducing the damage done by ROS to a cell, a tissue or an organ that has been removed from an animal. This method comprising contacting the cell, tissue or organ with a solution or medium containing an effective amount of a metal-binding compound of the invention. The invention further provides novel metal-binding compounds, pharmaceutical compositions comprising the metal-binding compounds, and kits comprising a container holding a metal-binding compound of the invention.

公开(公告)号：US20030055003A1

公开(公告)日：2003-03-20

申请号：US10199285

申请日：2002-07-19

Inventor： David Bar-Or ,  Richard L. Yukl

IPC: A61K038/00 ,  C07K005/00 ,  C07K007/00 ,  A61K038/06 ,  A61K038/04 ,  C07K017/00 ,  C07K016/00

CPC classification number: C07K5/1021 ,  A61K38/4866 ,  C07K5/0215 ,  C07K5/0606 ,  C07K5/081 ,  C07K5/1013 ,  C07K7/06 ,  C12N9/6464 ,  C12Y304/21069 ,  A61K2300/00

Abstract: The present invention is based on the unexpected discovery that activated protein C (APC) is inactivated by copper. Accordingly, the invention provides improved methods of treating diseases and conditions treatable with APC which utilize a copper chelator to inhibit the inactivation of APC by copper.

Abstract translation: 本发明基于意想不到的发现，即活化蛋白C（APC）被铜灭活。 因此，本发明提供了治疗可用APC治疗的疾病和病症的改进方法，其利用铜螯合剂来抑制铜被APC灭活。

公开(公告)号：US20030044427A1

公开(公告)日：2003-03-06

申请号：US10161499

申请日：2002-06-03

Inventor： Peter M. Howley ,  John Benson ,  Hiroaki Kasukawa

IPC: A61K038/00 ,  A61K039/12 ,  C07K007/00 ,  C07K017/00 ,  A61K038/04 ,  C07K014/00 ,  C07H021/04 ,  C07K005/00 ,  C07K016/00 ,  A61K038/12 ,  C07K001/00 ,  C12P021/08

CPC classification number: G01N33/5011 ,  A61K38/00 ,  A61K48/00 ,  C07K14/005 ,  C07K2319/00 ,  C12N2710/20022 ,  G01N33/5008 ,  G01N33/502 ,  G01N33/5044 ,  G01N33/68

Abstract: By virtue of the present invention, there is provided methods and compositions for interfering with the proliferation of cells infected and/or transformed by papillomaviruses. The processes and compositions of this invention may be used to treat any mammal, including humans. According to this invention, mammals are treated by the pharmaceutically acceptable administration of an E2 peptidomimetic to reduce the symptoms of the specific papillomavirus-associated disease, or to prevent their recurrence.